HER2-targeted antibody–drug conjugates for breast cancer: ancestry and dose adjustment for thrombocytopenia

BACKGROUND: Thrombocytopenia is a common adverse event on HER2-targeted therapies, fam-trastuzumab deruxtecan (T-DXd) and ado-trastuzumab emtansine (T-DM1). A reported association of Asian ancestry with this event merits investigation to rule out potential confounding. METHODS: Subjects in this retr...

Descripción completa

Detalles Bibliográficos
Autores principales: Rainone, Michael, Behrendt, Carolyn E., Kasparian, Saro, Nguyen, Tina, Sedrak, Mina S., Lavasani, Sayeh, Stewart, Daphne B., Yuan, Yuan, Mortimer, Joanne E., Waisman, James R., Patel, Niki, Pullarkat, Vinod
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Nature Singapore 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10404202/
https://www.ncbi.nlm.nih.gov/pubmed/37326930
http://dx.doi.org/10.1007/s12282-023-01473-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10404202/
https://www.ncbi.nlm.nih.gov/pubmed/37326930
http://dx.doi.org/10.1007/s12282-023-01473-2

Ejemplares similares